Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $113.50 | 4 | 61.2% |
| Education | $72.00 | 1 | 38.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $103.20 | 2 | $0 (2024) |
| PFIZER INC. | $63.19 | 2 | $0 (2022) |
| LEO Pharma Inc. | $19.11 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $72.00 | 1 | Janssen Biotech, Inc. ($72.00) |
| 2022 | $94.39 | 3 | PFIZER INC. ($63.19) |
| 2021 | $19.11 | 1 | LEO Pharma Inc. ($19.11) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $72.00 | General |
| Category: Immunology | ||||||
| 12/14/2022 | PFIZER INC. | EUCRISA (Drug), CIBINQO | Food and Beverage | In-kind items and services | $32.27 | General |
| Category: DERMATOLOGY | ||||||
| 10/20/2022 | PFIZER INC. | EUCRISA (Drug), CIBINQO | Food and Beverage | In-kind items and services | $30.92 | General |
| Category: DERMATOLOGY | ||||||
| 08/23/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $31.20 | General |
| Category: Immunology | ||||||
| 06/10/2021 | LEO Pharma Inc. | ENSTILAR (Drug) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: DERMATOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 347 | 645 | $83,628 | $49,154 |
| 2022 | 11 | 297 | 511 | $72,383 | $42,892 |
| 2021 | 14 | 339 | 617 | $83,776 | $48,210 |
| 2020 | 8 | 128 | 192 | $28,899 | $15,875 |
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 80 | 202 | $23,180 | $15,370 | 66.3% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 34 | 58 | $10,573 | $6,334 | 59.9% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2023 | 28 | 48 | $10,460 | $5,868 | 56.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 15 | 32 | $7,797 | $5,243 | 67.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 29 | 36 | $5,842 | $3,276 | 56.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 38 | 38 | $6,389 | $3,154 | 49.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 26 | $4,367 | $2,688 | 61.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 34 | 62 | $6,712 | $2,678 | 39.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 22 | 29 | $4,092 | $2,037 | 49.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $3,276 | $1,848 | 56.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 19 | 84 | $771.12 | $587.50 | 76.2% |
| 87220 | Tissue fungi or parasites | Office | 2023 | 16 | 17 | $170.00 | $71.06 | 41.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 64 | 162 | $18,590 | $12,510 | 67.3% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2022 | 32 | 53 | $11,549 | $6,661 | 57.7% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 16 | 33 | $8,041 | $5,139 | 63.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 24 | 47 | $8,568 | $4,858 | 56.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 33 | $5,543 | $3,610 | 65.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 30 | 30 | $5,044 | $2,841 | 56.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 33 | 57 | $6,171 | $2,558 | 41.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 27 | 30 | $4,868 | $2,555 | 52.5% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 15 | 18 | $2,046 | $1,161 | 56.8% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 14 | 14 | $1,652 | $768.45 | 46.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 18 | 34 | $312.12 | $230.91 | 74.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 50 | 100 | $16,796 | $11,002 | 65.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 40 | 86 | $9,869 | $7,433 | 75.3% |
About Dr. Gary Oliver, MD
Dr. Gary Oliver, MD is a Dermatology healthcare provider based in Daly City, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073599411.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Oliver, MD has received a total of $185.50 in payments from pharmaceutical and medical device companies, with $72.00 received in 2024. These payments were reported across 5 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($113.50).
As a Medicare-enrolled provider, Oliver has provided services to 1,111 Medicare beneficiaries, totaling 1,965 services with total Medicare billing of $156,131. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Other Specialties Dermatopathology, Anatomic Pathology
- Location Daly City, CA
- Active Since 12/19/2005
- Last Updated 01/11/2012
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1073599411
Products in Payments
- TREMFYA (Drug) $72.00
- EUCRISA (Drug) $63.19
- REMICADE (Biological) $31.20
- ENSTILAR (Drug) $19.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.